Dolby Laboratories Reports Fourth Quarter And Fiscal Year 2024 Financial Results
| DOLBY LABORATORIES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts; unaudited) |
|||||
| |
|||||
| |
Fiscal Quarter Ended |
|
Fiscal Year Ended |
||
| |
September 27, |
September 29, |
|
September 27, |
September 29, |
| Revenue: |
|
|
|
|
|
| Licensing |
$ |
$ |
|
$ |
$ |
| Products and services |
22,101 |
25,359 |
|
91,927 |
101,814 |
| Total revenue |
304,806 |
290,562 |
|
1,273,721 |
1,299,744 |
| |
|
|
|
|
|
| Cost of revenue: |
|
|
|
|
|
| Cost of licensing |
18,764 |
14,556 |
|
67,204 |
64,890 |
| Cost of products and services |
15,232 |
20,996 |
|
73,292 |
87,676 |
| Total cost of revenue |
33,996 |
35,552 |
|
140,496 |
152,566 |
| |
|
|
|
|
|
| Gross profit |
270,810 |
255,010 |
|
1,133,225 |
1,147,178 |
| |
|
|
|
|
|
| Operating expenses: |
|
|
|
|
|
| Research and development |
68,636 |
70,426 |
|
263,663 |
271,523 |
| Sales and marketing |
87,901 |
90,870 |
|
334,460 |
354,364 |
| General and administrative |
69,209 |
66,612 |
|
270,392 |
258,477 |
| Restructuring charges/(credits) |
(1,290) |
30,596 |
|
6,384 |
47,061 |
| Total operating expenses |
224,456 |
258,504 |
|
874,899 |
931,425 |
| |
|
|
|
|
|
| Operating income/(loss) |
46,354 |
(3,494) |
|
258,326 |
215,753 |
| |
|
|
|
|
|
| Other income/(expense): |
|
|
|
|
|
| Interest income/(expense), net |
6,854 |
9,280 |
|
34,077 |
28,086 |
| Other income, net |
6,526 |
3,247 |
|
20,076 |
6,214 |
| Total other income |
13,380 |
12,527 |
|
54,153 |
34,300 |
| |
|
|
|
|
|
| Income before income taxes |
59,734 |
9,033 |
|
312,479 |
250,053 |
| (Provision for)/benefit from income taxes |
(868) |
875 |
|
(48,163) |
(48,409) |
| Net income including noncontrolling interest |
58,866 |
9,908 |
|
264,316 |
201,644 |
| Less: net income attributable to noncontrolling interest |
(296) |
(722) |
|
(2,491) |
(988) |
| Net income attributable to Dolby Laboratories, Inc. |
$ |
$ |
|
$ |
$ |
| |
|
|
|
|
|
| Net income per share: |
|
|
|
|
|
| Basic |
$ |
$ |
|
$ |
$ |
| Diluted |
$ |
$ |
|
$ |
$ |
| Weighted-average shares outstanding: |
|
|
|
|
|
| Basic |
95,395 |
95,701 |
|
95,544 |
95,771 |
| Diluted |
96,593 |
97,678 |
|
97,325 |
97,733 |
| DOLBY LABORATORIES, INC. CONSOLIDATED BALANCE SHEETS (in thousands; unaudited) |
||
| |
||
| |
September 27, |
September 29, |
| ASSETS |
|
|
| Current assets: |
|
|
| Cash and cash equivalents |
$ |
$ |
| Restricted cash |
95,705 |
72,602 |
| Short-term investments |
- |
139,148 |
| Accounts receivable, net |
315,465 |
262,245 |
| Contract assets, net |
197,478 |
182,130 |
| Inventories, net |
33,728 |
35,623 |
| Prepaid expenses and other current assets |
69,994 |
50,692 |
| Total current assets |
1,194,417 |
1,487,804 |
| Long-term investments |
89,267 |
97,812 |
| Property, plant, and equipment, net |
479,109 |
481,581 |
| Operating lease right-of-use assets |
39,046 |
40,199 |
| Goodwill and intangible assets, net |
967,722 |
575,836 |
| Deferred taxes |
219,758 |
201,860 |
| Other non-current assets |
120,609 |
94,674 |
| Total assets |
$ |
$ |
| |
|
|
| LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
| Current liabilities: |
|
|
| Accounts payable |
$ |
$ |
| Accrued liabilities |
347,529 |
351,399 |
| Income taxes payable |
9,045 |
4,769 |
| Contract liabilities |
31,644 |
31,505 |
| Operating lease liabilities |
12,238 |
13,628 |
| Total current liabilities |
417,836 |
422,226 |
| Non-current contract liabilities |
34,593 |
39,997 |
| Non-current operating lease liabilities |
34,754 |
37,020 |
| Other non-current liabilities |
135,852 |
108,339 |
| Total liabilities |
623,035 |
607,582 |
| |
|
|
| Stockholders' equity: |
|
|
| Class |
53 |
53 |
| Class B common stock |
41 |
41 |
| Retained earnings |
2,496,255 |
2,391,990 |
| Accumulated other comprehensive loss |
(19,187) |
(36,984) |
| Total stockholders' equity – Dolby Laboratories, Inc. |
2,477,162 |
2,355,100 |
| Noncontrolling interest |
9,731 |
17,084 |
| Total stockholders' equity |
2,486,893 |
2,372,184 |
| Total liabilities and stockholders' equity |
$ |
$ |
| DOLBY LABORATORIES, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands; unaudited) |
||
| |
||
| |
Fiscal Year Ended |
|
| |
September 27, |
September 29, |
| Operating activities: |
|
|
| Net income including noncontrolling interest |
$ |
$ |
| Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
75,559 |
82,558 |
|
|
119,825 |
118,486 |
|
|
11,768 |
12,956 |
|
|
(2,919) |
(860) |
|
|
(2,256) |
(793) |
|
|
(21,612) |
(18,337) |
|
|
- |
16,225 |
|
|
(10,828) |
(2,800) |
|
|
|
|
| Accounts receivable, net |
(28,967) |
47,779 |
| Contract assets, net |
(8,707) |
347 |
| Inventories |
(2,654) |
(13,226) |
| Operating lease right-of-use assets |
(8,420) |
(8,817) |
| Prepaid expenses and other assets |
10,097 |
3,868 |
| Accounts payable and accrued liabilities |
(34,554) |
(52,315) |
| Income taxes, net |
(4,501) |
(8,722) |
| Contract liabilities |
(9,738) |
(8,379) |
| Operating lease liabilities |
(5,263) |
(5,818) |
| Other non-current liabilities |
(13,894) |
3,285 |
| Net cash provided by operating activities |
327,252 |
367,081 |
| |
|
|
| Investing activities: |
|
|
| Purchases of marketable securities |
(160,198) |
(172,955) |
| Proceeds from sales of marketable securities |
234,061 |
54,964 |
| Proceeds from maturities of marketable securities |
157,729 |
176,833 |
| Purchases of property, plant, and equipment |
(30,007) |
(30,339) |
| Business combinations, net of cash and restricted cash acquired |
(487,877) |
25,703 |
| Net cash provided by/(used in) investing activities |
(286,292) |
54,206 |
| |
|
|
| Financing activities: |
|
|
| Proceeds from issuance of common stock |
40,203 |
47,781 |
| Repurchase of common stock |
(160,001) |
(149,276) |
| Payment of cash dividend |
(114,579) |
(103,407) |
| Distributions to noncontrolling interest |
(5,164) |
(266) |
| Purchase of noncontrolling interest in business combinations |
(9,920) |
- |
| Equity issued in connection with business combination |
722 |
- |
| Shares repurchased for tax withholdings on vesting of restricted stock |
(39,075) |
(31,144) |
| Payment of deferred consideration for prior business combinations |
- |
(500) |
| Net cash used in financing activities |
(287,814) |
(236,812) |
| |
|
|
| Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash |
6,640 |
5,120 |
| Net increase/(decrease) in cash, cash equivalents, and restricted cash |
(240,214) |
189,595 |
| Cash, cash equivalents, and restricted cash at beginning of period |
817,966 |
628,371 |
| Cash, cash equivalents, and restricted cash at end of period |
$ |
$ |
| Licensing Revenue by Market |
|||||||||||
| |
|||||||||||
| The following table presents the composition of our licensing revenue and percentage of total licensing revenue for all periods presented (in thousands, except percentage amounts): |
|||||||||||
| |
|||||||||||
| |
Fiscal Quarter Ended |
|
Fiscal Year Ended |
||||||||
| Market |
September 27, 2024 |
|
September 29, 2023 |
|
September 27, 2024 |
|
September 29, 2023 |
||||
| Broadcast |
$ |
34 |
|
$ |
39 |
|
$ |
35 |
|
$ |
38 |
| Mobile |
48,701 |
17 |
|
36,122 |
14 |
|
235,774 |
20 |
|
243,897 |
20 |
| CE |
42,024 |
15 |
|
41,682 |
16 |
|
165,817 |
14 |
|
170,197 |
14 |
| PC |
34,077 |
12 |
|
27,240 |
10 |
|
141,300 |
12 |
|
124,362 |
10 |
| Other |
62,124 |
22 |
|
57,711 |
21 |
|
229,798 |
19 |
|
207,755 |
18 |
| Total licensing revenue |
$ |
100 |
|
$ |
100 |
|
$ 1,181,794 |
100 |
|
$ |
100 |
| GAAP to Non-GAAP Reconciliations |
||||||
| (unaudited) |
||||||
| |
|
|
|
|
|
|
| The following tables present Dolby's GAAP financial measures reconciled to the non-GAAP financial measures included in this release for the fourth quarter and fiscal years ended September |
||||||
| |
|
|
|
|
|
|
| Net income: |
|
Fiscal Quarter Ended |
|
Fiscal Year Ended |
||
| (in thousands) |
|
September 27, |
September 29, |
|
September 27, |
September 29, |
| GAAP net income attributable to Dolby Laboratories, Inc. |
|
$ |
$ |
|
$ |
$ |
| Stock-based compensation (1) |
|
29,679 |
28,195 |
|
119,825 |
118,486 |
| Amortization of acquisition-related intangibles (2) |
|
6,296 |
3,306 |
|
15,552 |
10,056 |
| Restructuring charges/(credits) |
|
(1,290) |
30,596 |
|
6,384 |
47,061 |
| Impact of Tax Reform |
|
(10,042) |
- |
|
(10,042) |
- |
| Income tax adjustments |
|
(4,777) |
(7,339) |
|
(24,528) |
(28,249) |
| Non-GAAP net income attributable to Dolby Laboratories, Inc. |
|
$ |
$ |
|
$ |
$ |
| |
|
|
|
|
|
|
| (1) Stock-based compensation included in above line items: |
|
|
|
|
|
|
| Cost of products and services |
|
$ |
$ |
|
$ |
$ |
| Research and development |
|
9,703 |
9,643 |
|
38,214 |
39,472 |
| Sales and marketing |
|
9,994 |
9,279 |
|
40,128 |
40,038 |
| General and administrative |
|
9,620 |
8,885 |
|
39,982 |
37,279 |
| |
|
|
|
|
|
|
| (2) Amortization of acquisition-related intangibles included in above line items: |
|
|
|
|
|
|
| Cost of licensing |
|
$ |
$ |
|
$ |
$ |
| Cost of products and services |
|
768 |
650 |
|
2,350 |
3,248 |
| Research and development |
|
- |
- |
|
- |
253 |
| Sales and marketing |
|
867 |
721 |
|
2,824 |
3,137 |
| General and administrative |
|
1,872 |
1,873 |
|
7,488 |
3,170 |
| |
|
|
|
|
|
|
| Diluted earnings per share: |
|
Fiscal Quarter Ended |
|
Fiscal Year Ended |
||
| |
|
September 27, |
September 29, |
|
September 27, |
September 29, |
| GAAP diluted earnings per share |
|
$ |
$ |
|
$ |
$ |
| Stock-based compensation |
|
0.30 |
0.29 |
|
1.23 |
1.21 |
| Amortization of acquisition-related intangibles |
|
0.06 |
0.03 |
|
0.16 |
0.10 |
| Restructuring charges/(credits) |
|
(0.01) |
0.31 |
|
0.07 |
0.48 |
| Impact of Tax Reform |
|
(0.10) |
- |
|
(0.11) |
- |
| Income tax adjustments |
|
(0.05) |
(0.07) |
|
(0.25) |
(0.28) |
| Non-GAAP diluted earnings per share |
|
$ |
$ |
|
$ |
$ |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Weighted-average shares outstanding - diluted (in thousands) |
|
96,593 |
97,678 |
|
97,325 |
97,733 |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| The following tables present a reconciliation between GAAP and non-GAAP versions of the estimated financial measures for the first quarter of fiscal 2025 and full year fiscal 2025 included in this release: |
||||||
| |
|
|
|
|
|
|
| Gross margin: |
|
|
Q1 2025 |
|
|
Fiscal 2025 |
| GAAP gross margin |
|
|
87.0 |
|
|
87.0 |
| Stock-based compensation |
|
|
0.1 |
|
|
0.1 |
| Amortization of acquisition-related intangibles |
|
|
2.9 |
|
|
2.9 |
| Non-GAAP gross margin |
|
|
90.0 |
|
|
90.0 |
| |
|
|
|
|
|
|
| Operating expenses (in millions): |
|
|
Q1 2025 |
|
|
Fiscal 2025 |
| GAAP operating expenses (low - high end of range) |
|
|
$230 - $240 |
|
|
$908 - $918 |
| Stock-based compensation |
|
|
(37) |
|
|
(134) |
| Amortization of acquisition-related intangibles |
|
|
(3) |
|
|
(9) |
| Non-GAAP operating expenses (low - high end of range) |
|
|
$190 - $200 |
|
|
$765 - $775 |
| |
|
|
|
|
|
|
| Operating margin: |
|
|
|
|
Fiscal 2025 |
|
| GAAP operating margin |
|
|
|
|
|
20% +/- |
| Stock-based compensation |
|
|
|
|
|
10 |
| Amortization of acquisition-related intangibles |
|
|
|
|
|
3 |
| Non-GAAP operating margin |
|
|
|
|
|
33% +/- |
| |
|
|
|
|
|
|
| Effective tax rate: |
|
|
|
|
|
Q1 2025 |
| GAAP effective tax rate |
|
|
|
|
|
20.5 |
| Stock-based compensation (low - high end of range) |
|
|
|
|
|
(2%) - 0% |
| Amortization of acquisition-related intangibles (low - high end of range) |
|
|
|
|
|
(1%) - 0% |
| Non-GAAP effective tax rate |
|
|
|
|
|
18.5 |
| |
|
|
|
|
|
|
| Diluted earnings per share: |
|
Q1 2025 |
|
Fiscal 2025 |
||
| |
|
Low |
High |
|
Low |
High |
| GAAP diluted earnings per share |
|
$ |
$ |
|
$ |
$ |
| Stock-based compensation |
|
0.39 |
0.39 |
|
1.39 |
1.39 |
| Amortization of acquisition-related intangibles |
|
0.12 |
0.12 |
|
0.45 |
0.45 |
| Income tax adjustments |
|
(0.08) |
(0.08) |
|
(0.28) |
(0.28) |
| Non-GAAP diluted earnings per share |
|
$ |
$ |
|
$ |
$ |
| |
|
|
|
|
|
|
| Weighted-average shares outstanding - diluted (in thousands) |
|
97,400 |
97,400 |
|
97,500 |
97,500 |
Investor Contact:
Peter Goldmacher
415-254-7415
[email protected]
Media Contact:
[email protected]
SOURCE Dolby Laboratories, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment